AMYRA Biotech AG
AMYRA Biotech AG is a Swiss joint stock company founded by serial entrepreneurs in the life sciences sector.
AMYRA is developing therapeutic product applications for the treatment of celiac disease and gluten sensitivity, which represent major public health issues. Both conditions are triggered by the ingestion of gluten.
Celiac patients suffer from extremely discomforting acute symptoms and have a high risk of developing serious long-term complications, including cancer, osteoporosis, arthritis, and others. Despite being the most common autoimmune disease worldwide, no effective treatment is available to date to address this vast unmet medical need.
AMYRA's novel product solutions are targeted to inhibit the toxic potential of gluten, thereby providing effect treatments for celiac disease and gluten sensitivity. AYMRA's products have the potential to establish a new standard of care and majorly impact the lives of affected people.